

Am 2
determinant of] an antigen presenting cell, said receptor being of a type that is internalized upon binding of a ligand and that transmits a signal in the antigen presenting cell that stimulates antigen processing and presentation by the antigen presenting cell, said targeting ligand being covalently linked to said immunogen, whereby binding of said molecular adjuvant to said antigen presenting cell receptor [determinant] activates said antigen presenting cell, effecting delivery of said immunogen to an antigen presenting pathway of said antigen presenting cell.

81
~~Cancel claim 2.~~

Am 3
3. (Amended) A molecular adjuvant as claimed in claim 1 [2], wherein said targeting ligand binds specifically to a receptor selected from the group consisting of C5a receptor, IFN-gamma receptor, [CD21 (] C3d[] receptor, [CD64 (FcγRI)] FcγRI receptor, and [CD23 (FcεRII)] FcεRII receptor.

Am 6
6. (Amended) A molecular adjuvant as claimed in claim 1, comprising [a targeting ligand and an immunogen having the sequence YKQGGFLGLYSFKPMPLaR] SEQ ID NO:2.

Am 4
25. (Amended) Antibodies to a selected immunogen, wherein the antibodies are produced by a method comprising the steps of:

Am 5
a) immunizing an animal with an immunogenically effective amount of the molecular adjuvant of claim 1, wherein the molecular adjuvant comprises the selected immunogen; and

b) recovering the antibodies from serum of the animal [the method of claim 24].

REMARKS

The Official Action dated November 8, 2000 has been carefully reviewed. In view of the amendments presented herewith and the following remarks, Applicants respectfully